Evidence map›Paper›PMID 23197309›Full record

ArticleInternational journal of cancer2013

Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.

Yasumichi Kuwahara, E Lorena Mora-Blanco, Fatima Banine, Arlin B Rogers, Christopher Fletcher, Larry S Sherman, Charles W M Roberts, Bernard E Weissman

Abstract read
In one paragraph

Article in International journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. High Frequency of Ovarian Cyst Development in VhlThe American journal of pathology · 2018
    Article
  3. SWI/SNF chromatin remodeling complexes and cancer.American journal of medical genetics. Part C, Seminars in medical genetics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Yasumichi KuwaharaUNC-Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7295, USA. weissman@med.unc.edu
E Lorena Mora-Blanco
Fatima Banine
Arlin B Rogers
Christopher Fletcher
Larry S Sherman
Charles W M Roberts
Bernard E Weissman
Oregon Health & Science University · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USHarvard University · USIn-Q-Tel · USUNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI FRUH, KLAUS J · 1985 to 2011
$140.8M
Systems Analysis of Cancer Pathways in Mouse ModelsU01CA105423 · NCI · DANA-FARBER CANCER INSTITUTE · PI ORKIN, STUART H · 2004 to 2013
$8.4M
THE FUNCTION OF SNF5 (SMARCB1), AN EPIGENETIC TUMOR SUPPRESSORR01CA113794 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 2005 to 2026
$7.8M
Role of hsnf5/BAF47 Loss in Human Cancer DevelopmentR01CA091048 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WEISSMAN, BERNARD E. · 2002 to 2012
$2.3M
REPRODUCTIVE STEROIDS AND EXPERIMENTAL STROKEK01RR000163 · NCRR · OREGON HEALTH AND SCIENCE UNIVERSITY · PI MURPHY, STEPHANIE J · 2000 to 2004
$479k
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA091048NCI NIH HHS R01CA091048NCI NIH HHS R01 CA113794NCI NIH HHS R01CA113794NCI NIH HHS U01 CA105423NCI NIH HHS U01CA105423NCRR NIH HHS K01 RR000163NCRR NIH HHS P51 RR000163NCRR NIH HHS RR00163
6 · The paper itself

Abstract

Malignant rhabdoid tumors (MRTs) are rare, aggressive cancers occuring in young children primarily through inactivation of the SNF5(INI1, SMARCB1) tumor suppressor gene. We and others have demonstrated that mice heterozygous for a Snf5 null allele develop MRTs with partial penetrance. We have also shown that Snf5(+/-) mice that lack expression of the pRb family, due to TgT121 transgene expression, develop MRTs with increased penetrance and decreased latency. Here, we report that altering the genetic background has substantial effects upon MRT development in Snf5(+/--) and TgT121 ;Snf5(+/-) mice, with a mixed F1 background resulting in increased latency and the appearance of brain tumors. We also report the establishment of the first mouse MRT cell lines that recapitulate many features of their human counterparts. Our studies provide further insight into the genetic influences on MRT development as well as provide valuable new cell culture and genetically engineered mouse models for the study of CNS-MRT etiology.

Indexed as

Cell Line, TumorAnimalsCell ProliferationCell Transformation, NeoplasticChoroid Plexus NeoplasmsChromosomal Proteins, Non-HistoneDisease Models, AnimalGenotypeHumansKaryotypeMiceMice, TransgenicPhenotypeRhabdoid TumorSMARCB1 ProteinChromosomal Proteins, Non-HistoneSMARCB1 ProteinSmarcb1 protein, mouse

Identifiers

PMID23197309
PMCPMC3605221
OpenAlexW2046295982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.